News

  Aarhus, Denmark March 14th, 2023: Teitur Trophics (“Teitur”), a biotech company dedicated to developing new treatments for patients suffering from neurodegenerative diseases, today announces the completion of a €28M Series A financing. The…

Teitur is happy to have secured funding from the Innobooster grant from Innovation Fund Denmark. The grant will allow the company to finalize studies to nominate a candidate for IND enabling studies

Teitur today announces the successful closing of a €400.000 convertible loan from Sunstone to advance the preclinical program targeting neurodegenerative diseases.

Teitur is happy to have secured funding from the Innobooster grant from Innovation Fund Denmark. The grant will enable the company to advance the innovative peptide project for treating patients suffering from Huntington’s Disease.

The pharma company Teitur Trophics that targets neurodegenerative diseases has joined the BII Creation House program. As part of the Creation House program, Teitur Trophics will have access to a global network of life…